For clinically important hypotension resulting primarily from vasodilation in the…. ANDA 209968, held by Avet Lifesciences. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 209968 (Phenylephrine Hydrochloride), held by Avet Lifesciences, was first approved by FDA on Feb 28, 2023, with 1 approved supplement and 0 published complete response letters.
Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Mar 11, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 28, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters